PREDICTION OF ALZHEIMER’S DISEASE USING AN AI DRIVEN SCREENING PLATFORM
PREDICTION OF ALZHEIMER’S DISEASE USING AN AI DRIVEN SCREENING PLATFORM
批准号:
10091560
负责人:
金额:
$150.87万
依托单位:
依托单位国家:
英国
项目类别:
EU-Funded
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Alzheimer’s disease (AD) and related disorders leading to dementia are associated with staggering costs and suffering. Recently, there has been some progress in the search for effective therapeutic interventions and it is clear that any treatment is likely to be most effective if administered at the earliest stage of disease, but the health care system is not ready for this new scenario. There is an urgent need, therefore, to establish scalable, cost-efficient diagnostic markers, tools and procedures that can identify people at increased risk, at point of care for stratification into personalized interventions to prevent or delay dementia. PREDICTOM will develop an open-source, interoperable and customisable biomarker screening platform, utilizing an existing online resource to save time and money, to generate an evidence base for general population screening for AD and related disorders. We will bring diagnostics closer to the patient by examining the feasibility of using samples which can be obtained at home (e.g. finger-prick blood, saliva (for genetics and epigenetics) and stool for microbiom) for diagnostic biomarker analysis. We will also evaluate innovative technologies for disease risk identification, including digital technologies and novel MRI, EEG, eye tracking, and blood-based biomarkers. The platform will use artificial intelligence models to analyse data from all biomarkers to identify users at high risk of developing dementia and to direct them to personalized intervention to prevent further cognitive decline and development of dementia. We will seek to facilitate a change in current healthcare practice for early diagnosis of AD through development of new clinical practice guidelines based on evidence generated in the project. By improving the ease of identification of those with early signs of dementia we expect to have a significant impact on personal and financial burden of dementia in Europe and across the world.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
年轻血清介导血管内皮细胞Cdk5负调控高反应性中性粒细胞浸润入脑减轻Alzheimer’s病的机制研究
-
批准号:82271473
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:祁方昉
-
依托单位:
雌激素GPR30受体通过调节神经免疫治疗Alzheimer's病的机制研究
-
批准号:32241007
-
项目类别:专项项目
-
资助金额:63.00万元
-
批准年份:2022
-
负责人:招明高
-
依托单位:
基于AKT/mTOR/HIF-1a信号轴调控糖代谢重编程探讨补阳还五汤减轻炎症防治Alzheimer病的机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:杨琳
-
依托单位:
流感疫苗联合PD-1抗体在Alzheimer’s病治疗中的作用及机制研究
-
批准号:81971021
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:祁方昉
-
依托单位:
多功能纳米探针的构建及其在Alzheimer 病细胞多模态成像的应用研究
-
批准号:2019JJ40399
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2019
-
负责人:丁萍
-
依托单位:
Aß3-10-KLH疫苗免疫防治Alzheimer病(AD)的机制探讨
-
批准号:81870819
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2018
-
负责人:曹云鹏
-
依托单位:
α7 nAChR调控线粒体自噬在Alzheimer病发病机制中的作用研究
-
批准号:81860207
-
项目类别:地区科学基金项目
-
资助金额:35.0万元
-
批准年份:2018
-
负责人:齐晓岚
-
依托单位:
F-18 标记β分泌酶1抑制剂用于Alzheimer 症早期诊断的基础研究
-
批准号:81771886
-
项目类别:面上项目
-
资助金额:25.0万元
-
批准年份:2017
-
负责人:李云春
-
依托单位:
流感疫苗调控Arginase1表达在减弱Alzheimer’s病理中的作用及机制研究
-
批准号:31700914
-
项目类别:青年科学基金项目
-
资助金额:26.0万元
-
批准年份:2017
-
负责人:祁方昉
-
依托单位:
Exendin-4通过Wnt通路减轻2型糖尿病大脑Alzheimer病样改变的机制
-
批准号:81770817
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2017
-
负责人:袁刚
-
依托单位: